Skip to main content
Unichem Laboratories Ltd. logo

Unichem Laboratories Ltd. — Investor Relations & Filings

Ticker · UNICHEMLAB ISIN · INE351A01035 LEI · 3358008AHXLO9H4C2Q20 BSE.NS Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2024-01-11 Regulatory Filings
Country IN India
Listing BSE.NS UNICHEMLAB

About Unichem Laboratories Ltd.

https://www.unichemlabs.com/

Unichem Laboratories Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs). The company provides solutions across various therapeutic areas, including cardiology, gastroenterology, anti-infectives, diabetology, orthopedics, and neurology. It maintains a significant international footprint, exporting products to regulated markets such as the United States and Europe. The manufacturing infrastructure is built to comply with global standards, featuring approvals from international regulatory agencies. Through its dedicated research and development initiatives, the organization develops a robust pipeline of generic products and complex formulations aimed at improving patient outcomes globally.

Recent filings

Filing Released Lang Actions
Press Release - ANDA approval from the USFDA for Unichem''s Doxazosin.
Regulatory Filings Classification · 95% confidence The document is a press release dated January 11, 2024, announcing the receipt of ANDA approval from the USFDA for Unichem Laboratories Limited's Doxazosin Tablets. It is addressed to stock exchanges under SEBI regulations and contains no financial statements or detailed financial data. The document is short (3323 characters) and serves as an announcement of a regulatory approval event rather than a financial report or detailed investor presentation. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is also not a certification or legal proceeding. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement under SEBI regulations about a significant company event (FDA approval) that does not fit other specific categories.
2024-01-11 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of ANDA approval from the USFDA for Unichem Laboratories' Doxazosin Tablets. It is addressed to stock exchanges under SEBI Regulation 30, which requires disclosure of material events. The content is a regulatory announcement about a product approval, not a financial report, earnings release, or management discussion. The document length is 3323 characters, which is relatively short and primarily serves as an announcement. There is no financial data, no discussion of financial results, no voting results, no management changes, or other report types. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-11 English
Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018 for quarter ended December 31, 2023.
Regulatory Filings Classification · 95% confidence The document is a compliance certificate issued under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation activities for the quarter ended December 31, 2023. It is addressed to stock exchanges and signed by the company secretary and the registrar & share transfer agent. The document is short (3334 characters) and primarily serves as a certification of regulatory compliance rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. It is a regulatory compliance certificate, which fits best under Regulatory Filings (RNS) as per the certification rule and fallback category.
2024-01-09 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a compliance certificate issued under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation activities for the quarter ended December 31, 2023. It is addressed to stock exchanges and signed by the company secretary and the registrar & share transfer agent. The document is short (3334 characters) and primarily serves as a certification of regulatory compliance rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. It is a regulatory compliance certificate, which fits best under Regulatory Filings (RNS) as per the classification rules, especially the Certification Rule and fallback category for miscellaneous filings.
2024-01-09 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a notice from Unichem Laboratories Limited addressed to stock exchanges regarding the closure of the trading window for insiders and designated persons. It references the upcoming financial results for the quarter and nine months ended December 31, 2023, but does not contain any financial data or results itself. The document is short (1440 characters) and serves as a regulatory compliance announcement related to insider trading restrictions around the earnings release period. It does not present financial statements, management discussion, or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous compliance and regulatory announcements that do not fit other categories.
2023-12-29 English
Closure of Trading Window.
Regulatory Filings Classification · 100% confidence The document is a notice from Unichem Laboratories Limited addressed to stock exchanges regarding the closure of the trading window for insiders and designated persons. It references the upcoming financial results for the quarter and nine months ended December 31, 2023, but does not contain any financial data or the results themselves. The document is short (1440 characters) and serves as a regulatory compliance announcement related to insider trading restrictions around the earnings release period. It is not a financial report, earnings release, or any detailed report but rather a regulatory filing informing the stock exchanges of the trading window closure. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-12-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.